Brelgometon
Brelgometon (ATH-1105) is an orally active HGF/MET positive modulator. Brelgometon activates downstream ERK and AKT cascades. Brelgometon reduces pro-inflammatory cytokine levels and extranuclear TDP-43 aggregation; it also upregulates EAAT2 expression and improves mitochondrial function. Brelgometon protects neurons from excitotoxicity, inflammation, oxidative stress and mitochondrial dysfunction; it also maintains neurite length, neuromuscular junction integrity and sciatic nerve function. Brelgometon alleviates motor function deterioration, maintains body weight and prolongs survival in ALS transgenic mice. Brelgometon is applicable to research related to amyotrophic lateral sclerosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3060541-19-4
- Formule: C21H28F3N3O2
- Masse moléculaire:411.46
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
Met |
EAAT2 |
In Vitro
Brelgometon (1 pM-10 nM; 15 min) positively regulates HGF-mediated MET phosphorylation in HEK293 cells, with significant enhancement observed at concentrations of 10 pM and 100 pM[1].
Brelgometon (1 μM; 20 min) positively regulates HGF-dependent intracellular signaling pathways in HEK293 cells, and significantly enhances the phosphorylation levels of ERK and AKT at a concentration of 1 μM[1].
Brelgometon (pre-incubated for 15 minutes, followed by co-incubation with neurotoxic insults for 24 hours) exerts neuroprotective effects on primary rat cortical neurons and maintains cell viability against multiple ALS-related neurotoxic insults[1].
Brelgometon (100 pM-1 μM; 15 min) protects primary rat spinal motor neurons from glutamate-induced excitotoxic injury, as evidenced by increased cell viability, preserved neurite structure, alleviated TDP-43 pathological changes, enhanced mitochondrial function, and inhibited caspase-3-mediated apoptosis[1].
Brelgometon (100 nM-1 μM; 23 h) exerts anti-inflammatory effects in LPS-activated BV2 microglia, reducing the production and gene expression of pro-inflammatory mediators[2].
Brelgometon (1 nM-1 μM; 20 min) protects rat primary motor neuron-astrocyte co-culture systems from glutamate-induced injury and ameliorates ALS-associated astrocyte dysfunction[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293 cells
-
Concentration:1 pM, 10 pM, 100 pM, 1 nM, 10 nM
-
Incubation Time:15 minutes
-
Result:Increased MET phosphorylation significantly at 10 pM relative to 1 ng/mL HGF alone.
Increased MET phosphorylation significantly at 100 pM relative to 1 ng/mL HGF alone.
-
Cell Line:human embryonic kidney 293 (HEK293) cells
-
Concentration:1 pM, 10 pM, 100 pM, 1 nM, 10 nM (MET phosphorylation assay); 1 μM (ERK/AKT phosphorylation assay)
-
Incubation Time:15 min (MET phosphorylation assay); 20 min (ERK/AKT phosphorylation assay)
-
Result:Significantly increased MET phosphorylation at 10 pM and 100 pM compared with 1 ng/mL HGF alone.
Significantly increased phosphorylation of both ERK and AKT at 1 μM compared with controls treated with 2 ng/mL HGF alone.
Parmacokinetics
| Species | Dose | Route | Cmax | AUC0-inf | Tmax | T1/2 |
|---|---|---|---|---|---|---|
| Mice[2] | 10 mg/kg | p.o. | 652 ng/mL | 611 ng·h/mL | 0.17 h | 0.78 h |
In Vivo
Brelgometon (10-20 mg/kg; daily; 2 months) dose-dependently preserves body weight, motor and nerve function, reduces inflammation and neurodegeneration biomarkers, and attenuates sciatic nerve pathology in Prp-TDP43A315T ALS mice, with the 20 mg/kg dose yielding the most robust effects[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TDP-43A315T hemizygous transgenic mice (male, 1-month-old, ALS model)[1]
-
Dosage:0.4 mg/kg; 2 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 2 months
-
Result:Increased average body weight at 10 and 11 weeks of age in mice treated with 2 mg/kg; increased average body weight at 9, 10, and 11 weeks of age in mice treated with 10 mg/kg, compared to vehicle-treated ALS mice.
Improved cross time after 1 and 2 months of treatment in the balance beam test with 10 mg/kg treatment.
Increased latency to fall after 2 months of treatment in the rotarod test with 2 mg/kg and 10 mg/kg treatments.
Improved grip strength after 1 and 2 months of treatment with 10 mg/kg treatment; improved grip strength after 2 months of treatment with 2 mg/kg treatment.
Increased latency to fall after 2 months of treatment in the Kondziela screen test with 2 mg/kg treatment; increased latency to fall after 1 and 2 months of treatment in the Kondziela screen test with 10 mg/kg treatment.
Increased compound muscle action potential (CMAP) amplitude after 1 and 2 months of treatment with 2 mg/kg and 10 mg/kg treatments.
Increased nerve conduction velocity (NCV) after 2 months of treatment with 2 mg/kg treatment; increased NCV after 1 and 2 months of treatment with 10 mg/kg treatment.
Decreased plasma tumor necrosis factor α (TNF-α) concentrations after 1 month of treatment with all three doses; decreased plasma TNF-α concentrations after 2 months of treatment with 2 mg/kg and 10 mg/kg doses.
Decreased plasma interleukin 6 (IL-6) concentrations after 1 month of treatment with 2 mg/kg and 10 mg/kg doses; decreased plasma IL-6 concentrations after 2 months of treatment with all three doses.
Decreased plasma neurofilament light chain (NfL) concentrations after 1 and 2 months of treatment with all three doses.
Increased the number of axons per area after 2 months of treatment with 2 mg/kg and 10 mg/kg treatments.
Increased mean axonal diameter after 2 months of treatment with all three doses; preserved large-diameter axons, resulting in an axon diameter distribution similar to wild-type mice.
Yielded lower g-ratios after 2 months of treatment with all three doses, normalizing the relationship between axon diameter and relative myelin thickness.
Chemical Information
-
CAS No. 3060541-19-4
-
Masse moléculaire 411.46
-
Formule C21H28F3N3O2
-
SMILES
C[C@@H](C(N(C1)C[C@@H](C)CC)=O)N(C(CC2)=O)C1N2CC3=CC=C(C=C3)C(F)(F)F
-
Synonyms
ATH-1105
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)